This case describes the clinical, biochemical and immunological features associated with relapse of thyrotoxicosis during pregnancy in a patient who had recently undergone a subtotal thyroidectomy for Graves' disease. The baby, shortly after birth, showed clinical and biochemical features of thyrotoxicosis which responded to carbimazole therapy. Thyrotropin receptor antibodies and thyroid stimulating antibodies were present in the blood of the mother and baby. The clinical course of the neonatal thyrotoxicosis correlated with the TSH receptor antibody levels.
Get full access to this article
View all access options for this article.
References
1.
HardistyCA, MunroDS. Serum long-acting thyroid stimulator protector in pregnancy complicated by Graves' disease. BMJ, 1983; 286: 934–935.
2.
MunroDS, DirmikisSM, HumphriesH, SmithT, BraidheadGD. The role of thyroid stimulating immunoglobulins of Graves' disease in neonatal thyrotoxicosis. Br. J Obs Gynae, 1978; 837–843.
3.
MaiseyMN, StimmterL.The role of long acting thyroid stimulator in neonatal thyrotoxicosis. Clin Endo, 1972; 1: 81–90.
4.
CrooksJ, Aboul-KhairSA, TurnbullAC, HyttenFE. The incidence of goitre during pregnancy. Lancet1964; 2: 334–338.
5.
MatsuuraN, FujiedaK, IidaY, FujimotoS, KonishiJ, KasagiK, HagisawaM, FukushiM, TakasugiN.TSH receptor antibodies in mothers with Graves' disease and outcome in their offspring. Lancet1988; 1: 14–17.
